Incorporating saponin-based SHP2 inhibitors into combination regimens using immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) offers a compelling approach to leverage SHP2’s role in the tumor microenvironment. Here, PTPN11 is linked to neoplasm.